

**FLUZONE HIGH-DOSE VACCINE:  
PROVEN TO PREVENT MORE CASES  
OF INFLUENZA IN ADULTS 65+**

Compared with Fluzone vaccine<sup>1,2</sup>

**NEARLY 70% OF ADULTS 65+ WHO WERE VACCINATED** AGAINST THE FLU  
RECEIVED FLUZONE HIGH-DOSE VACCINE IN THE UNITED STATES IN 2017<sup>3</sup>

According to a head-to-head study published in the *New England Journal of Medicine* in August 2014 that spanned 2 flu seasons,<sup>2</sup> **FLUZONE HIGH-DOSE VACCINE PROVIDED:**

PRIMARY ENDPOINT

**24.2%**

**BETTER PROTECTION**  
from influenza disease

compared with Fluzone vaccine,  
when caused by viral strains  
regardless of their antigenic  
similarity to vaccine components<sup>1,2</sup>

Primary endpoint of the study was the occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.

SECONDARY ENDPOINT

**51.1%**

**BETTER PROTECTION**  
from influenza disease

compared with Fluzone  
vaccine, when caused  
by viral strains similar  
to vaccine components<sup>1,2</sup>

A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention-defined influenza-like illness.

Study population: 31,803 adults ranging from 65 to 100 years of age (with a median age of 70 years).<sup>1,a</sup>

<sup>a</sup>Per-protocol analysis set for efficacy assessments.<sup>1</sup>

**THE BENEFITS OF FLUZONE HIGH-DOSE  
VACCINE**

- Contains 4x the antigen per strain of standard-dose inactivated influenza vaccine<sup>1,4</sup>
- Covered by Medicare Part B and most Medicare Advantage plans with no copay
- Designed specifically for adults 65+

**CHOOSE FLUZONE HIGH-DOSE VACCINE  
TO HELP PROTECT YOUR PATIENTS 65+**

**NEARLY 90 MILLION  
DOSES SOLD IN  
THE UNITED STATES  
SINCE 2009<sup>5</sup>**



## IMPORTANT SAFETY INFORMATION FOR FLUZONE HIGH-DOSE VACCINE

Fluzone High-Dose vaccine should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks.

The most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur. Vaccination with Fluzone High-Dose vaccine may not protect all individuals.

## INDICATION FOR FLUZONE HIGH-DOSE VACCINE

Fluzone High-Dose vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine. Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older.

Before administration, please see the full Prescribing Information for Fluzone High-Dose vaccine.

Fluzone High-Dose vaccine is manufactured and distributed by Sanofi Pasteur Inc.

Fluzone High-Dose vaccine (CPT<sup>®a</sup> code 90662) is a covered benefit under Medicare Part B.

<sup>a</sup>CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

**References:** **1.** Fluzone High-Dose vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **2.** DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med.* 2014;371:635-645. **3.** Sanofi Pasteur Inc. Data on file (Fluzone High-Dose vaccine claims data based on IQVIA claims data calculations), January 2018. MKT32881. **4.** Monto AS, Ansalidi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. *Vaccine.* 2009;27:5043-5053. **5.** Sanofi Pasteur Inc. Data on file (Fluzone High-Dose vaccine doses sold, 2009-January 25, 2018), January 2018. MKT32864.

  
**Fluzone<sup>®</sup> High-Dose**  
**INFLUENZA VACCINE**  
Senior Strength